Home › Companies › ENANTA PHARMACEUTICALS INC. › 2024-2025

ENANTA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ENANTA PHARMACEUTICALS INC.’s Form 8-K, filed 2025-03-17 (Item 5.07 on EDGAR). Page generated 04 October 2026.

8Reported items
129Asset managers
1,143Fund votes
2025-03-13Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ENANTA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ENANTA PHARMACEUTICALS INC.

These tallies are ENANTA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-03-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ENANTA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-03-13
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mark G. Foletta	14,935,940	--	--	622,935	2,257,476	Majority: yes
Elect Director: Lesley Russell, MBChB, MRCP	14,574,902	--	--	983,973	2,257,476	Majority: yes
Proposal 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 800,000 shares.	11,435,985	4,085,303	37,587	--	2,257,476	Majority: yes
Proposal 4: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.	14,516,861	1,039,888	2,126	--	2,257,476	Majority: yes
Proposal 5: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2025 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registe	17,740,127	72,357	3,867	--	0	Majority: yes

Source: ENANTA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-03-17 — read the filing on EDGAR.

How asset managers voted at the ENANTA PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 129 asset managers that disclosed a ENANTA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ENANTA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 14,516,861AGAINST: 1,039,888

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers. The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”): 14,516,861 for, 1,039,888 against, per its Form 8-K filed 2025-03-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 21,332,544 outstanding shares: 68% for, 5% against (73% of the company cast a for/against vote).

The 127 asset managers below cast 93% of the shares they voted on this item FOR (9,626,938 for, 775,086 against).

FOR 93%7%

FOR: 9,626,938 (92.5%)AGAINST: 775,086 (7.5%)ONE YEAR: 30 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the p” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	2,074,256	0	For
BlackRock	1,817,812	0	For
FARALLON CAPITAL MANAGEMENT LLC	1,065,788	0	For
MARSHALL WACE, LLP	477,524	0	For
Stonepine Capital Management, LLC	434,316	0	For
Fidelity	386,893	0	For
GEODE CAPITAL MANAGEMENT, LLC	371,254	0	For
State Street	356,648	117	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	348,749	0	For
Charles Schwab	309,150	0	For
Dimensional	0	249,751	Against
DE Shaw	210,075	0	For
JPMorgan	190,323	0	For
Northern Trust	178,514	0	For
Thrivent	169,466	0	For
Renaissance	158,262	0	For
UBS	0	148,960	Against
Two Sigma	115,272	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	95,630	0	For
RA CAPITAL MANAGEMENT, L.P.	83,190	0	For
American Century	0	75,050	Against
Invesco	0	73,103	Against
Equitable	67,795	0	For
MELLON INVESTMENTS Corp	66,166	0	For
Prudential/PGIM	54,364	4,820	For

Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.

2. To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

11%ONE YEAR 54.7%1 YEAR 32%

The 122 asset managers below cast 100% of the shares they voted on this item FOR (1,076,901 for, 0 against).

FOR: 1,076,901 (10.9%)ONE YEAR: 5,385,287 (54.7%)1 YEAR: 3,113,739 (31.6%)THREE YEARS: 259,834 (2.6%)3 YEARS: 7,119 (0.1%)1-YEAR: 50 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to our na” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	0	One Year
BlackRock	0	1 Year
FARALLON CAPITAL MANAGEMENT LLC	1,065,788	For
MARSHALL WACE, LLP	0	1 Year
Fidelity	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
State Street	0	One Year
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	One Year
Charles Schwab	0	1 Year
Dimensional	0	Three Years
DE Shaw	0	One Year
Northern Trust	0	1 Year
Thrivent	0	One Year
Renaissance	0	One Year
UBS	0	One Year
Two Sigma	0	One Year
JACOBS LEVY EQUITY MANAGEMENT, INC	0	1 Year
RA CAPITAL MANAGEMENT, L.P.	0	One Year
JPMorgan	0	1 Year
American Century	0	One Year
Invesco	0	One Year
Equitable	0	One Year
MELLON INVESTMENTS Corp	0	One Year
Prudential/PGIM	0	1 Year
Columbia Threadneedle	0	One Year

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

3. TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST 26%

FOR: 11,435,985AGAINST: 4,085,303

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: To Approve an Amendment to Our 2019 Equity Incentive Plan. The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance unde”): 11,435,985 for, 4,085,303 against, per its Form 8-K filed 2025-03-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 21,332,544 outstanding shares: 53.6% for, 19% against (73% of the company cast a for/against vote).

The 48 asset managers below cast 81% of the shares they voted on this item FOR (3,697,270 for, 885,170 against).

FOR 81%AGAINST 19%

FOR: 3,697,270 (80.7%)AGAINST: 885,170 (19.3%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	2,006,078	50,391	For
BlackRock	1,052,518	0	For
Fidelity	341,541	12,509	For
Dimensional	0	215,202	Against
Charles Schwab	154,575	0	For
Thrivent	0	83,632	Against
JPMorgan	0	76,659	Against
Equitable	37,855	29,940	For
Columbia Threadneedle	0	58,898	Against
TIAA	0	55,049	Against
BRIDGEWAY FUNDS INC	0	45,000	Against
QUANTITATIVE MASTER SERIES LLC	37,640	0	For
American Century	0	37,525	Against
AIG/SunAmerica	0	31,896	Against
Nationwide	1,776	29,505	Against
Invesco	0	30,612	Against
Northern Trust	0	22,348	Against
Prudential/PGIM	17,500	4,820	For
Lincoln Financial	0	18,878	Against
GuideStone	0	18,754	Against
Brighthouse	0	17,641	Against
MASTER INVESTMENT PORTFOLIO	11,800	0	For
Global X	11,417	0	For
Pacific Life	10,024	0	For
Bridge Builder Trust	8,949	0	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

4. To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2025 fiscal year.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%

FOR: 17,740,127AGAINST: 72,357

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 5: To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2025 Fiscal Year. The stockholders ratified the appointment of PricewaterhouseCoopers ”): 17,740,127 for, 72,357 against, per its Form 8-K filed 2025-03-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 21,332,544 outstanding shares: 83% for, 0.4% against (83% of the company cast a for/against vote).

The 48 asset managers below cast 99.9% of the shares they voted on this item FOR (4,582,271 for, 169 against).

FOR 99.9%

FOR: 4,582,271 (100.0%)AGAINST: 169 (0.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting f” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	2,056,469	For
BlackRock	1,052,518	For
Fidelity	354,050	For
Dimensional	215,202	For
Charles Schwab	154,575	For
Thrivent	83,632	For
JPMorgan	76,659	For
Equitable	67,795	For
Columbia Threadneedle	58,898	For
TIAA	55,049	For
BRIDGEWAY FUNDS INC	45,000	For
QUANTITATIVE MASTER SERIES LLC	37,640	For
American Century	37,525	For
AIG/SunAmerica	31,896	For
Nationwide	31,281	For
Invesco	30,612	For
Northern Trust	22,348	For
Prudential/PGIM	22,320	For
Lincoln Financial	18,878	For
GuideStone	18,754	For
Brighthouse	17,641	For
MASTER INVESTMENT PORTFOLIO	11,800	For
Global X	11,417	For
Pacific Life	10,024	For
Bridge Builder Trust	8,949	For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

5. To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Lesley Russell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 14,574,902WITHHELD: 983,973

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lesley Russell, MBChB, MRCP”): 14,574,902 for, 983,973 withheld, per its Form 8-K filed 2025-03-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 21,332,544 outstanding shares: 68% for, 5% withheld (73% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (4,457,882 for, 0 against).

FOR 97%

FOR: 4,457,882 (97.3%)ABSTAIN: 124,530 (2.7%)

Largest asset managers voting on “To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respect” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,056,469	0	For
BlackRock	1,052,518	0	For
Fidelity	354,050	0	For
Dimensional	215,202	0	For
Charles Schwab	154,575	0	For
Thrivent	83,632	0	For
JPMorgan	76,659	0	For
Equitable	37,855	29,940	For
Columbia Threadneedle	58,898	0	For
TIAA	55,049	0	For
BRIDGEWAY FUNDS INC	0	45,000	Abstain
QUANTITATIVE MASTER SERIES LLC	37,640	0	For
American Century	37,525	0	For
AIG/SunAmerica	31,896	0	For
Nationwide	31,281	0	For
Invesco	0	30,612	Abstain
Northern Trust	22,348	0	For
Prudential/PGIM	22,320	0	For
Lincoln Financial	18,878	0	For
GuideStone	18,754	0	For
Brighthouse	17,641	0	For
MASTER INVESTMENT PORTFOLIO	11,800	0	For
Global X	0	11,417	Abstain
Pacific Life	10,024	0	For
Bridge Builder Trust	8,949	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

6. To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Mark G. Foletta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 14,935,940WITHHELD: 622,935

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mark G. Foletta”): 14,935,940 for, 622,935 withheld, per its Form 8-K filed 2025-03-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 21,332,544 outstanding shares: 70% for, 3% withheld (73% of the company cast a for/withheld vote).

The 47 asset managers below cast 100% of the shares they voted on this item FOR (4,505,499 for, 0 against).

FOR 98%

FOR: 4,505,499 (98.3%)ABSTAIN: 76,913 (1.7%)

Largest asset managers voting on “To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respect” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,056,469	0	For
BlackRock	1,052,518	0	For
Fidelity	354,050	0	For
Dimensional	215,202	0	For
Charles Schwab	154,575	0	For
Thrivent	83,632	0	For
JPMorgan	76,659	0	For
Equitable	37,855	29,940	For
Columbia Threadneedle	58,898	0	For
TIAA	55,049	0	For
BRIDGEWAY FUNDS INC	0	45,000	Abstain
QUANTITATIVE MASTER SERIES LLC	37,640	0	For
American Century	37,525	0	For
AIG/SunAmerica	31,896	0	For
Nationwide	31,281	0	For
Invesco	30,612	0	For
Northern Trust	22,348	0	For
Prudential/PGIM	22,320	0	For
Lincoln Financial	18,878	0	For
GuideStone	18,754	0	For
Brighthouse	17,641	0	For
MASTER INVESTMENT PORTFOLIO	11,800	0	For
Global X	11,417	0	For
Pacific Life	10,024	0	For
Bridge Builder Trust	8,949	0	For

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

7. 14A Executive Compensation Vote Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

1 96%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (28 for, 0 against).

FOR: 28 (3.9%)1: 690 (96.1%)

Largest asset managers voting on “14A Executive Compensation Vote Frequency” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COURIER CAPITAL LLC	0	0	0	0	1
VOISARD ASSET MANAGEMENT GROUP, INC.	28	0	0	0	For

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 132,418 (100.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at ENANTA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
JPMorgan	0	0	0	0	One Year
GuideStone	0	0	0	0	One Year

Largest ENANTA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of ENANTA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 21,332,544 shares outstanding at the time of that meeting.

Top ENANTA PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	9.72%
2	BlackRock	8.52%
3	FARALLON CAPITAL MANAGEMENT LLC	5.00%
4	MARSHALL WACE, LLP	2.24%
5	Stonepine Capital Management, LLC	2.04%
6	Fidelity	1.81%
7	GEODE CAPITAL MANAGEMENT, LLC	1.74%
8	State Street	1.67%
9	PARAMETRIC PORTFOLIO ASSOCIATES LLC	1.63%
10	Charles Schwab	1.45%

Reported ENANTA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ENANTA PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
JANUS HENDERSON GROUP PLC	16.38%	13G
Dapice Joshua J.	13.20%	13G
Farallon Capital Management, LLC	9.88%	DEF14A
BlackRock	9.46%	13F
Vanguard Group	9.41%	13F
Jay R. Luly, Ph.D.	7.99%	13D
Krensavage Asset Management, LLC	7.02%	DEF14A
Millennium Management	6.31%	13F
Morgan Stanley	5.17%	DEF14A
Integrated Core Strategies (US) LLC	3.12%	13G

Percentages above are of 21,332,544 shares outstanding, as reported by ENANTA PHARMACEUTICALS INC. on its Form 10-Q dated 2025-02-04 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ENANTA PHARMACEUTICALS INC.’s 10-Q dated 2025-02-04. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At ENANTA PHARMACEUTICALS INC.'s shareholder meeting held 2025-03-13, in the 2024-2025 proxy season, 129 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,143 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers, as… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ENANTA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-03-17.

ENANTA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.